Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034502 · ClinicalTrials.gov registry record · Phase 1
A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00034502: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT00034502 is a Phase 1 study that has completed, run by Eli Lilly and Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00034502, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
This is a non-randomized study in patients who have received prior 5-FU therapy for colorectal cancer. The objective of this trial is to establish a maximum tolerated dose of ALIMTA and irinotecan given in combination as well as to assess the safety and efficacy of this combination for patients with locally advanced or metastatic colorectal cancer. ALIMTA and irinotecan will be given every 21 days.
Interventions
- DRUG irinotecan
- DRUG ALIMTA
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
What the finished NCT00034502 record still lists
NCT00034502 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which irinotecan is the first listed.
NCT00034502 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00034502 about?
NCT00034502 is a clinical study titled "A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.". This is a non-randomized study in patients who have received prior 5-FU therapy for colorectal cancer. The objective of this trial is to establish a maximum tolerated dose of ALIMTA and irinotecan given in combination as well as to assess the safety and efficacy of this combination for patients with...
What is the current status of trial NCT00034502?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00034502?
The interventions under investigation include: irinotecan (DRUG), ALIMTA (DRUG).
Who is sponsoring clinical trial NCT00034502?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.